Kenvue (KVUE) is a global leader in consumer health, offering trusted brands such as Tylenol, Neutrogena, Listerine, Aveeno, and BAND-AID to over 1.2 billion people worldwide. Backed by science and healthcare expertise, its portfolio consists of self-care, skin health, beauty, and essential health products.
Spun off from Johnson & Johnson (JNJ) in 2023, it has operations across North America, Europe, Asia Pacific, Latin America, and the Middle East, with its headquarters in New Jersey, United States.
-
This AI Stock Is Cheaper Than AMD and Crushing It in Returns
-
A $1 Billion Reason to Buy AMD Stock Now
-
Earnings, Manufacturing Data and Other Can’t Miss Items this Week
-
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.
Today, Kimberly-Clark (KMB) announced that it intends to buy Kenuve for $48.7 billion. The deal is expected to close in 2026. KVUE stock has shot up about 14% today in response.
KVUE stock has exhibited shaky performance in 2025, with a five-day gain of approximately 9% and a one-month increase of 4%. However, almost all of this gain is from the past 24 hours, as the acquisition news broke. Over the past six months, the stock has declined close to 31%, while the 52-week return stands at about 28%, widely underperforming the market index S&P 500’s ($SPX) gain of 20% in the same period.
Kenvue Inc. reported its Q2 2025 financial results with revenues of $1.35 billion, slightly beating analyst estimates of $1.31 billion. The company posted an EPS of $0.56, surpassing the consensus expectations of $0.54, driven by strong product demand and stable pricing across its consumer health portfolio.
This solid top- and bottom-line performance highlights Kenvue’s effective market positioning and operational efficiency amid moderate economic uncertainty.
Deeper financial analysis reveals improved gross margins of 45%, reflecting a favorable product mix and cost optimization initiatives. Operating expenses remained controlled, boosting operating income by 6% year-over-year (YoY). The company reported cash and cash equivalents of $620 million, down marginally from the previous quarter but supported by healthy free cash flow. Dividend payouts continued steadily, emphasizing Kenvue’s commitment to shareholder returns.
Looking forward, Kenvue provided guidance projecting Q3 2025 revenue between $1.37 billion and $1.42 billion, with EPS expected in the range of $0.57 to $0.60. Management highlighted ongoing investments in innovation and strategic marketing to sustain growth while cautiously monitoring inflationary pressures and supply chain conditions.
About the Author
